RSS Alerts

Latest News

view more

Podcasts

  • Evotec strengthens and expands its Alliance Business
    Dr Mark Ashton is Executive Vice President, Business Development of Evotec and is responsible for Evotec's commercial and partnering activities. Prior to assuming responsibility for Business Development in 2005, Dr Ashton held a number of positions within Operations at Evotec: He joined the Company in 1995 as one of the initial employees of the Discovery Division, becoming Department Manager in 2001, Director of Chemistry Services in 2002 and taking over responsibility for Evotec's Discovery Services Division in 2004, where he had responsibility for Evotec's screening, parallel synthesis and medicinal chemistry operations. During his time at Evotec, Dr Ashton has managed a wide range of pharmaceutical and biotechnology related projects, including medicinal chemistry projects, design and synthesis of screening libraries and technology transfer projects and has been involved in the progression of a number of drug candidates into the clinic in numerous therapeutic areas. Dr Ashton has authored and co-authored a number of peer reviewed papers, articles and book chapters in addition to being named on a number of pharmaceutical patents. He is trained as a medicinal chemist. Prior to joining Evotec, Dr Ashton also had spells at ICI Pharmaceuticals and Organon Laboratories. Mark Whittaker is Senior Vice President Drug Discovery at Evotec where he manages a large drug discovery collaboration and the groups of computational chemistry and structural biology. Before joining Evotec in 2001, Mark spent 13 years at British Biotech Pharmaceuticals where he led a number of medicinal chemistry programmes and was latterly Director of Chemistry. At British Biotech, Mark contributed to the discovery and development of six compounds that have progressed into human clinical trials. Before his career at British Biotech, Mark carried out post-doctoral research at the University of Oxford and at York University, Toronto and obtained a D. Phil in Chemistry from the University of York.
  • The Ubiquitin Story
    In this podcast interview with Drug Discovery Today, Nobel Prize winner Professor Aaron Ciechanover will talk about his career, his Nobel Prize-winning discovery of the UPS, and the extraordinary opportunities and challenges for drug discovery in this area.
  • Califf, Behrman and Kramer discuss the Clinical Trials Transformation Initiative.
    Download the Califf, Behrman and Kramer podcast as an mp3 file
  • Dr Brent Vose outlines AstraZeneca's oncology pipeline.
    Download the Dr. Brent Vose podcast as an mp3 file
view more

Webinars

  • Drug Delivery: enabling technology for discovery and development
    The integration of pharmacodynamic and pharmacokinetic parameters in non clinical pharmacology studies is a key aspect in drug discovery for efficacy and safety assessment, in the particular for the translation from the non clinical to the clinical field. Modeling the profile of plasma exposure achieved with the intended therapeutic route often requires the use of intravenous infusion. In addition, in most cases infusion parameters (infusion rate, volume, duration and sequences) need to be customized to achieve the appropriate pattern of plasma drug exposure. When pharmacodynamic parameters are recorded by telemetry, the use of implantable pumps rather than external pumps is necessary to preserve the improvement in physiological data recording offered by telemetry.
  • Enhancing productivity and accuracy in drug metabolism studies with the latest Orbitrap technology
    This webinar explores how productivity and accuracy in drug metabolism studies can be improved by employing the latest advancement in Orbitrap technology in pharmaceutical science and related industries
  • Part 2: How has HR-MS technology fundamentally changed the way we study drug biotransformation and disposition?
    AB SCIEX is proud to present the 2nd installment of a Global 4-Part Live Webinar Series exploring novel and dynamic workflows for Metabolite Identification & Drug Metabolism solutions as it pertains to the 4 main stages of the drug discovery and development paradigm, Lead Discovery, Late Stage Discovery, Early Development and Late Stage Development. Part 2 of this webinar series will focus on how HRMS technology has fundamentally changed the way metabolite biotransformations are investigated in Lead Discovery.
  • Industrialized Global Metabolite ID Solutions in the New Drug Discovery and Development Paradigm.
    AB SCIEX is proud to present the initial installment of a Global 4-Part Live Webinar Series exploring novel and dynamic workflows for Metabolite Identification & Drug Metabolism solutions as it pertains to the 4 main stages of the drug discovery and development paradigm, Lead Discovery, Late Stage Discovery, Early Development and Late Stage Development. Part 1 of this webinar series will focus on uniquely intelligent HRMS workflows for metabolite ID in Lead Discovery.
view more

Features

  • Drug discovery in the era of Facebook—new tools for scientific networking
    This article is involved with the impact that social networking is beginning to make on drug discovery process. While bioinformaticsand chemoinformatics underpin research at a scientific level, rapid communication between individual researchers across continents now allows the global exchange of ideas, tools and technologies.Networking at this level of speed and reach is quite a recent phenomenon. It facilitates the developmentof common interests, accelerates technology transfer and increases cooperative and competitive behaviour. The article critically evaluates different web-based networking approaches as effectivere sources for the drug discovery scientist.
  • Drug Discovery Today: highlighted review. ‘Metabolite-likeness’ as a criterion in the design and selection of pharmaceutical drug libraries
    This highlighted review from Drug Discovery Today by Dobson, Patel and Kell outlines how "metabolite-likeness" in an analogous manner to "drug-likeness" and "lead-likeness" can be used to improve the value of compound libraries design by incorporating features of endogenous metabolites ("endogenites")
  • Most downloaded review Q1 2009: Target discovery from data mining approaches
    The most downloaded review article from Drug Discovery Today from the first quarter of 2009 deals with the topic of target discovery from the informatics perspective. It would be difficult to overstate the value to Pharma of identifying and validating the most relevant therapeutic targets. In this article, Yang, Adelstein and Kassis outline text mining, its value and limitations and application to target discovery. In addition, they cover the field of emerging and integrated data mining approaches.
view more

Downloads

  • A quality alert and call for improved curation of public chemistry databases
    The quality of much of the chemical structure-based data introduced to the public domain is poor. The authors of this editorial describe some of the errors found in the recently released NIH Chemical Genomics Center ‘NPC browser’ database as an example.
  • Clinical and biological data integration for biomarker discovery
    In this review the authors have integrated parameters across clinical trials and associated genetic, gene expression and protein data. They provide examples to illustrate the utility of data integration to explore disease heterogeneity and develop predictive biomarkers.
  • A structural informatics approach to mine kinase knowledge bases
    In this article, the authors describe a combination of structural informatics approaches developed to mine data extracted from existing structure knowledge bases (Protein Data Bank and the GVK database) with a focus on kinase ATP-binding site data.
  • Current trends in antimicrobial agent research: chemo- and bioinformatics approaches
    This article reviews progress in the development of computational methods, tools and databases used for organizing and extracting biological meaning from antimicrobial research.
  • A quality alert and call for improved curation of public chemistry databases
    In the last ten years, public online databases have rapidly become trusted valuable resources upon which researchers rely for their chemical structures and data for use in cheminformatics, bioinformatics, systems biology, translational medicine and now drug repositioning or repurposing efforts. Their utility depends on the quality of the underlying molecular structures used. Unfortunately, the quality of much of the chemical structure-based data introduced to the public domain is poor. As an example we describe some of the errors found in the recently released NIH Chemical Genomics Center ‘NPC browser’ database as an example. There is an urgent need for government funded data curation to improve the quality of internet chemistry and to limit the proliferation of errors and wasted efforts.
view more

25 Hottest Articles

view more
Copyright © 2012
Elsevier Ltd. All rights reserved.
Terms & Conditions | Privacy | Website Design Working with water